
    
      This study is a randomized, double-blind, placebo-controlled, single dose (SD) and multiple
      dose (MD) administration study.

      Primary Objective: Safety and tolerability;

      Secondary Objective:

        1. Antiviral activity of T101 (HBsAg levels).

        2. Cellular (HBV-specific) and humoral (AD5 neutralizing antibodies, NAd5) immune responses
           to T101.

      Key Inclusion Criteria:

        1. Chronic hepatitis B patients with positive HBsAg.

        2. Patients must be receiving antiviral treatment with nucleoside analogs and have negative
           HBV DNA (defined as HBV DNA <20 IU/mL).
    
  